California State Teachers Retirement System Sells 82,134 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

California State Teachers Retirement System trimmed its holdings in MaxCyte, Inc. (NASDAQ:MXCT) by 91.5% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 7,581 shares of the company’s stock after selling 82,134 shares during the quarter. California State Teachers Retirement System’s holdings in MaxCyte were worth $32,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. BNP Paribas Financial Markets bought a new stake in shares of MaxCyte during the 4th quarter valued at about $56,000. Deutsche Bank AG grew its stake in shares of MaxCyte by 65.0% during the 4th quarter. Deutsche Bank AG now owns 98,436 shares of the company’s stock valued at $409,000 after purchasing an additional 38,782 shares during the period. Hsbc Holdings PLC lifted its position in shares of MaxCyte by 51.4% during the 4th quarter. Hsbc Holdings PLC now owns 48,791 shares of the company’s stock valued at $199,000 after buying an additional 16,554 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of MaxCyte by 47.9% during the 4th quarter. Renaissance Technologies LLC now owns 281,200 shares of the company’s stock valued at $1,170,000 after buying an additional 91,100 shares in the last quarter. Finally, Two Sigma Advisers LP purchased a new position in shares of MaxCyte during the 4th quarter valued at about $74,000. 68.81% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Wall Street Zen raised MaxCyte from a “sell” rating to a “hold” rating in a research report on Sunday, June 8th. BTIG Research set a $6.00 price objective on MaxCyte and gave the company a “buy” rating in a research report on Wednesday, March 12th. Finally, Stifel Nicolaus lowered their price objective on MaxCyte from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, March 12th.

MaxCyte Stock Performance

NASDAQ MXCT opened at $2.27 on Friday. The company has a market cap of $241.56 million, a P/E ratio of -6.68 and a beta of 1.27. The business’s 50 day moving average price is $2.45 and its 200-day moving average price is $3.40. MaxCyte, Inc. has a fifty-two week low of $2.10 and a fifty-two week high of $5.20.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10). The company had revenue of $10.39 million for the quarter, compared to the consensus estimate of $9.05 million. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. As a group, equities analysts predict that MaxCyte, Inc. will post -0.42 EPS for the current year.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.